IgA Nephropathy
IgA Nephropathy
Advertisement
Vlado Perkovic, MBBS, PhDASN Kidney Week 2024 | December 4, 2024
Vlado Perkovic spoke about findings from the FLOW, APPLAUSE-IgAN, and CREDENCE trials presented at ASN Kidney Week.
View More
Charlotte RobinsonIgA Nephropathy | November 25, 2024
A study examined a possible link between IgA nephropathy (IgAN) and inflammatory skin diseases.
Charlotte RobinsonIgA Nephropathy | November 27, 2024
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
Charlotte RobinsonIgA Nephropathy | November 20, 2024
Could the systemic inflammatory response index (SIRI) be a useful measure of renal prognosis in IgA nephropathy (IgAN)?
Charlotte RobinsonIgA Nephropathy | November 20, 2024
Diffuse magnetic imaging resonance shows promise for evaluating clinical and pathological changes in patients with IgAN.
Charlotte RobinsonIgA Nephropathy | October 11, 2024
Purespring Therapeutics received $105M in Series B funding to develop gene therapies for kidney diseases, including IgAN.
Charlotte RobinsonASN Kidney Week 2024 | October 8, 2024
Long-term results of a study of atacicept to treat IgA nephropathy (IgAN) will be presented at ASN Kidney Week.
Charlotte RobinsonIgA Nephropathy | October 30, 2024
It is important to know the risks versus benefits of a reduced-dose methylprednisolone regimen in high-risk IgAN patients.
Charlotte RobinsonIgA Nephropathy | October 30, 2024
Patients with both IgAN and C2 lesions displayed a poor clinical prognosis requiring more effective treatment strategies.
Charlotte RobinsonIgA Nephropathy | October 30, 2024
There is a need to identify prognostic bio­markers of IgA nephropathy (IgAN) that can be used in clinical practice.
Charlotte RobinsonIgA Nephropathy | October 2, 2024
Researchers developed an updated pediatric prediction tool to determine risk for IgA nephropathy (IgAN) post-biopsy.
Charlotte RobinsonIgA Nephropathy | October 2, 2024
Researchers studied the prognostic value of a new inflammatory biomarker, the systemic immune inflammation index, in IgAN.
Charlotte RobinsonIgA Nephropathy | September 11, 2024
A new project will improve medical record access and data research awareness among patients with IgA nephropathy (IgAN).
Charlotte RobinsonIgA Nephropathy | October 2, 2024
The impact of glomerular IgM deposit on the progression of IgA nephropathy (IgAN) is unclear.
Charlotte RobinsonIgA Nephropathy | September 6, 2024
NephCure has announced the first IgA Nephropathy (IgAN) Awareness Day, happening September 26, 2024.
Charlotte RobinsonIgA Nephropathy | September 6, 2024
The FDA has granted full approval to sparsentan to slow kidney function decline in adults with primary IgA nephropathy.
Charlotte RobinsonIgA Nephropathy | August 29, 2024
Information on a possible association between chronic tonsillitis and IgA nephropathy (IgAN) has been lacking.
Charlotte RobinsonIgA Nephropathy | August 29, 2024
Prevalence of IgA nephropathy (IgAN) and a summary of treatment patterns across Asian countries are lacking.
Charlotte RobinsonIgA Nephropathy | August 29, 2024
Urinary inflammatory biomarkers may be considered as alternative predictive biomarkers in patients with IgAN.
Charlotte RobinsonIgA Nephropathy | August 21, 2024
Researchers studied the LM pattern of glomerular injury and mesangial C3 staining in IgA nephropathy (IgAN).
Advertisement
Advertisement
Advertisement
Latest News

December 9, 2024